{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:07:25Z","timestamp":1788286045375,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NIH\/NCI","award":["CA286160"],"award-info":[{"award-number":["CA286160"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01755-6","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:00:06Z","timestamp":1762959606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["MicroRNA-142 improves IL1RAP CAR-T cell activity in acute myeloid leukemia"],"prefix":"10.1186","volume":"18","author":[{"given":"Kaito","family":"Harada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miso","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yile","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bea","family":"Parcutela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yead","family":"Jewel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlie","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idoroenyi","family":"Amanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le Xuan Truong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Ghoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"1755_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:502\u201326.","journal-title":"Am J Hematol"},{"key":"1755_CR2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3324\/haematol.2022.280801","volume":"108","author":"S Kayser","year":"2023","unstructured":"Kayser S, Levis MJ. The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica. 2023;108:308\u201320.","journal-title":"Haematologica"},{"key":"1755_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","volume":"20","author":"D Vetrie","year":"2020","unstructured":"Vetrie D, Helgason GV, Copland M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer. 2020;20:158\u201373.","journal-title":"Nat Rev Cancer"},{"key":"1755_CR4","first-page":"2813","volume":"141","author":"F El Chaer","year":"2023","unstructured":"El Chaer F, Hourigan CS, Zeidan AM. How i treat AML incorporating the updated classifications and guidelines. Blood. 2023;141:2813\u201323.","journal-title":"Blood"},{"key":"1755_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01217","volume":"9","author":"C Sweeney","year":"2019","unstructured":"Sweeney C, Vyas P. The graft-versus-leukemia effect in AML. Front Oncol. 2019;9:1217.","journal-title":"Front Oncol"},{"key":"1755_CR6","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","volume":"35","author":"N Daver","year":"2021","unstructured":"Daver N, Alotaibi AS, B\u00fccklein V, Subklewe M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 2021;35:1843\u201363.","journal-title":"Leukemia"},{"key":"1755_CR7","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317.","journal-title":"N Engl J Med"},{"key":"1755_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"1755_CR9","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera J-M, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836\u201347.","journal-title":"N Engl J Med"},{"key":"1755_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0603-7","volume":"11","author":"Y Wang","year":"2018","unstructured":"Wang Y, Xu Y, Li S, Liu J, Xing Y, Xing H, et al. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells. J Hematol Oncol. 2018;11:60.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"1755_CR11","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/leu.2017.147","volume":"31","author":"L Chen","year":"2017","unstructured":"Chen L, Mao H, Zhang J, Chu J, Devine S, Caligiuri MA, et al. Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Leukemia. 2017;31(8):1830\u20134.","journal-title":"Leukemia"},{"key":"1755_CR12","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1089\/hum.2017.241","volume":"29","author":"S Li","year":"2018","unstructured":"Li S, Tao Z, Xu Y, Liu J, An N, Wang Y, et al. CD33-specific chimeric antigen receptor T cells with different co-stimulators showed potent anti-leukemia efficacy and different phenotype. Hum Gene Ther. 2018;29:626\u201339.","journal-title":"Hum Gene Ther"},{"key":"1755_CR13","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/ijc.33865","volume":"150","author":"Y Liu","year":"2022","unstructured":"Liu Y, Wang S, Schubert M-L, Lauk A, Yao H, Blank MF, et al. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Int J Cancer. 2022;150:1141\u201355.","journal-title":"Int J Cancer"},{"key":"1755_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01092-4","volume":"14","author":"Q Cui","year":"2021","unstructured":"Cui Q, Qian C, Xu N, Kang L, Dai H, Cui W, et al. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2021;14:82.","journal-title":"J Hematol Oncol"},{"key":"1755_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00536-x","volume":"11","author":"N Chen","year":"2021","unstructured":"Chen N, Xu Y, Mou J, Rao Q, Xing H, Tian Z, et al. Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood Cancer J. 2021;11:144.","journal-title":"Blood Cancer J"},{"key":"1755_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0553-5","volume":"11","author":"J Wang","year":"2018","unstructured":"Wang J, Chen S, Xiao W, Li W, Wang L, Yang S, et al. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol. 2018;11:7.","journal-title":"J Hematol Oncol"},{"key":"1755_CR17","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","volume":"122","author":"A Mardiros","year":"2013","unstructured":"Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122:3138\u201348.","journal-title":"Blood"},{"key":"1755_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.580328","volume":"11","author":"L Driouk","year":"2020","unstructured":"Driouk L, Gicobi JK, Kamihara Y, Rutherford K, Dranoff G, Ritz J, et al. Chimeric antigen receptor T cells targeting NKG2D-ligands show robust efficacy against acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Front Immunol. 2020;11:580328.","journal-title":"Front Immunol"},{"key":"1755_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1282","volume":"10","author":"A Hasegawa","year":"2021","unstructured":"Hasegawa A, Saito S, Narimatsu S, Nakano S, Nagai M, Ohnota H, et al. Mutated GM-CSF-based CAR-T cells targeting CD116\/CD131 complexes exhibit enhanced anti-tumor effects against acute myeloid leukaemia. Clin Transl Immunol. 2021;10:e1282.","journal-title":"Clin Transl Immunol"},{"key":"1755_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41434-021-00283-5","volume":"29","author":"JT Zoine","year":"2022","unstructured":"Zoine JT, Prince C, Story JY, Branella GM, Lytle AM, Fedanov A, et al. Thrombopoietin-based CAR-T cells demonstrate in vitro and in vivo cytotoxicity to MPL positive acute myelogenous leukemia and hematopoietic stem cells. Gene Ther. 2022;29:1\u201312.","journal-title":"Gene Ther"},{"key":"1755_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100850","volume":"50","author":"E O\u2019Reilly","year":"2021","unstructured":"O\u2019Reilly E, Zeinabad HA, Szegezdi E. Hematopoietic versus leukemic stem cell quiescence: challenges and therapeutic opportunities. Blood Rev. 2021;50:100850.","journal-title":"Blood Rev"},{"key":"1755_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cells13181596","author":"E Bartoszewska","year":"2024","unstructured":"Bartoszewska E, Tota M, Kisielewska M, Skowron I, Sebastianka K, Stefaniak O, et al. Overcoming antigen escape and T-cell exhaustion in CAR-T therapy for leukemia. Cells. 2024. https:\/\/doi.org\/10.3390\/cells13181596.","journal-title":"Cells"},{"key":"1755_CR23","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","volume":"122","author":"F Mussai","year":"2013","unstructured":"Mussai F, De Santo C, Abu-Dayyeh I, Booth S, Quek L, McEwen-Smith RM, et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood. 2013;122:749\u201358.","journal-title":"Blood"},{"key":"1755_CR24","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1007\/s00277-024-06117-9","volume":"103","author":"C Zha","year":"2024","unstructured":"Zha C, Yang X, Yang J, Zhang Y, Huang R. Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies. Ann Hematol. 2024;103:4883\u201399.","journal-title":"Ann Hematol"},{"key":"1755_CR25","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","volume":"30","author":"AS Bhagwat","year":"2024","unstructured":"Bhagwat AS, Torres L, Shestova O, Shestov M, Mellors PW, Fisher HR, et al. Cytokine-mediated CAR T therapy resistance in AML. Nat Med. 2024;30:3697\u2013708.","journal-title":"Nat Med"},{"key":"1755_CR26","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood.2024024063","volume":"145","author":"S Haubner","year":"2025","unstructured":"Haubner S, Subklewe M, Sadelain M. Honing CAR t cells to tackle acute myeloid leukemia. Blood. 2025;145:1113\u201325.","journal-title":"Blood"},{"key":"1755_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/imm.13462","volume":"166","author":"A Zarezadeh Mehrabadi","year":"2022","unstructured":"Zarezadeh Mehrabadi A, Aghamohamadi N, Khoshmirsafa M, Aghamajidi A, Pilehforoshha M, Massoumi R, et al. The roles of interleukin-1 receptor accessory protein in certain inflammatory conditions. Immunology. 2022;166:38\u201346.","journal-title":"Immunology"},{"key":"1755_CR28","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1084\/jem.20180147","volume":"215","author":"K Mitchell","year":"2018","unstructured":"Mitchell K, Barreyro L, Todorova TI, Taylor SJ, Antony-Debr\u00e9 I, Narayanagari S-R, et al. IL1RAP potentiates multiple oncogenic signaling pathways in AML. J Exp Med. 2018;215:1709\u201327.","journal-title":"J Exp Med"},{"key":"1755_CR29","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1182\/blood-2012-01-404699","volume":"120","author":"L Barreyro","year":"2012","unstructured":"Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood. 2012;120:1290\u20138.","journal-title":"Blood"},{"key":"1755_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01586-x","volume":"17","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Park M, Ghoda LY, Zhao D, Valerio M, Nafie E, et al. IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells. J Hematol Oncol. 2024;17:67.","journal-title":"J Hematol Oncol"},{"key":"1755_CR31","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1182\/blood-2016-02-695312","volume":"128","author":"T-C Ho","year":"2016","unstructured":"Ho T-C, LaMere M, Stevens BM, Ashton JM, Myers JR, O\u2019Dwyer KM, et al. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood. 2016;128:1671\u20138.","journal-title":"Blood"},{"key":"1755_CR32","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1182\/blood-2015-11-679928","volume":"128","author":"B Zhang","year":"2016","unstructured":"Zhang B, Chu S, Agarwal P, Campbell VL, Hopcroft L, J\u00f8rgensen HG, et al. Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells. Blood. 2016;128:2671\u201382.","journal-title":"Blood"},{"key":"1755_CR33","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1182\/blood-2012-09-458935","volume":"121","author":"M Askmyr","year":"2013","unstructured":"Askmyr M, \u00c5gerstam H, Hansen N, Gordon S, Arvanitakis A, Rissler M, et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood. 2013;121:3709\u201313.","journal-title":"Blood"},{"key":"1755_CR34","doi-asserted-by":"publisher","first-page":"10786","DOI":"10.1073\/pnas.1422749112","volume":"112","author":"H \u00c5gerstam","year":"2015","unstructured":"\u00c5gerstam H, Karlsson C, Hansen N, Sand\u00e9n C, Askmyr M, von Palffy S, et al. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. Proc Natl Acad Sci U S A. 2015;112:10786\u201391.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1755_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56383-y","volume":"16","author":"F Chen","year":"2025","unstructured":"Chen F, Zhao D, Xu Y, Zhang Y, Chen M-H, Pathak KV, et al. Mir-142 deficit in T cells during blast crisis promotes chronic myeloid leukemia immune escape. Nat Commun. 2025;16:1253.","journal-title":"Nat Commun"},{"key":"1755_CR36","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1084\/jem.20151159","volume":"212","author":"MD Buck","year":"2015","unstructured":"Buck MD, O\u2019Sullivan D, Pearce EL. T cell metabolism drives immunity. J Exp Med. 2015;212:1345\u201360.","journal-title":"J Exp Med"},{"key":"1755_CR37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.stem.2022.12.006","volume":"30","author":"L Han","year":"2023","unstructured":"Han L, Dong L, Leung K, Zhao Z, Li Y, Gao L, et al. METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism. Cell Stem Cell. 2023;30:52-68.e13.","journal-title":"Cell Stem Cell"},{"key":"1755_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003752","author":"Y-C Kuo","year":"2022","unstructured":"Kuo Y-C, Kuo C-F, Jenkins K, Hung AF-H, Chang W-C, Park M, et al. Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-003752.","journal-title":"J Immunother Cancer"},{"key":"1755_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41167-z","volume":"14","author":"B Zhang","year":"2023","unstructured":"Zhang B, Zhao D, Chen F, Frankhouser D, Wang H, Pathak KV, et al. Acquired miR-142 deficit in leukemic stem cells suffices to drive chronic myeloid leukemia into blast crisis. Nat Commun. 2023;14:5325.","journal-title":"Nat Commun"},{"key":"1755_CR40","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1182\/blood-2012-03-415067","volume":"120","author":"NA Zorko","year":"2012","unstructured":"Zorko NA, Bernot KM, Whitman SP, Siebenaler RF, Ahmed EH, Marcucci GG, et al. Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. Blood. 2012;120:1130\u20136.","journal-title":"Blood"},{"key":"1755_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01133-y","volume":"14","author":"B Zhang","year":"2021","unstructured":"Zhang B, Nguyen LXT, Zhao D, Frankhouser DE, Wang H, Hoang DH, et al. Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML. J Hematol Oncol. 2021;14:122.","journal-title":"J Hematol Oncol"},{"key":"1755_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004222","author":"R Trad","year":"2022","unstructured":"Trad R, Warda W, Alcazer V, Neto da Rocha M, Berceanu A, Nicod C, et al. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-004222.","journal-title":"J Immunother Cancer"},{"key":"1755_CR43","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1158\/0008-5472.CAN-18-1078","volume":"79","author":"W Warda","year":"2019","unstructured":"Warda W, Larosa F, Neto Da Rocha M, Trad R, Deconinck E, Fajloun Z, et al. CML hematopoietic stem cells expressing IL1RAP can be targeted by chimeric antigen receptor-engineered T cells. Cancer Res. 2019;79:663\u201375.","journal-title":"Cancer Res"},{"key":"1755_CR44","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht J, Sun J, Eyquem J, Ho Y-J, Zhao Z, Leibold J, et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med. 2019;25:82\u20138.","journal-title":"Nat Med"},{"key":"1755_CR45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41577-019-0203-y","volume":"20","author":"NM Chapman","year":"2020","unstructured":"Chapman NM, Boothby MR, Chi H. Metabolic coordination of T cell quiescence and activation. Nat Rev Immunol. 2020;20:55\u201370.","journal-title":"Nat Rev Immunol"},{"key":"1755_CR46","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41416-021-01657-7","volume":"126","author":"D Robbrecht","year":"2022","unstructured":"Robbrecht D, Jungels C, Sorensen MM, Spanggaard I, Eskens F, Fretland S\u00d8, et al. First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours. Br J Cancer. 2022;126:1010\u20137.","journal-title":"Br J Cancer"},{"key":"1755_CR47","doi-asserted-by":"crossref","unstructured":"Guedan S, Calderon H, Posey AD Jr, Maus MV. Engineering and design of chimeric antigen receptors. Mol Ther. 2019;12:145\u201356.","DOI":"10.1016\/j.omtm.2018.12.009"},{"key":"1755_CR48","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4\u20131BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581\u201390.","journal-title":"Nat Med"},{"key":"1755_CR49","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jmb.2014.11.017","volume":"427","author":"JT Koerber","year":"2015","unstructured":"Koerber JT, Hornsby MJ, Wells JA. An improved single-chain Fab platform for efficient display and recombinant expression. J Mol Biol. 2015;427:576\u201386.","journal-title":"J Mol Biol"},{"key":"1755_CR50","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","volume":"123","author":"S Gill","year":"2014","unstructured":"Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014;123:2343\u201354.","journal-title":"Blood"},{"key":"1755_CR51","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3324\/haematol.2014.112748","volume":"100","author":"C O\u2019Hear","year":"2015","unstructured":"O\u2019Hear C, Heiber JF, Schubert I, Fey G, Geiger TL. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. Haematologica. 2015;100:336\u201344.","journal-title":"Haematologica"},{"key":"1755_CR52","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/leu.2015.52","volume":"29","author":"SS Kenderian","year":"2015","unstructured":"Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJD, et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. 2015;29:1637\u201347.","journal-title":"Leukemia"},{"key":"1755_CR53","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739\u201348.","journal-title":"Nat Med"},{"key":"1755_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1165870","volume":"14","author":"C Aparicio-P\u00e9rez","year":"2023","unstructured":"Aparicio-P\u00e9rez C, Carmona M, Benabdellah K, Herrera C. Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL. Front Immunol. 2023;14:1165870.","journal-title":"Front Immunol"},{"key":"1755_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1582944","volume":"16","author":"B Xue","year":"2025","unstructured":"Xue B, Liu Y, Li B, Lu Y, Zhou L, Ye S, et al. Comparison of efficacy and adverse effects of CD19\/20 CART versus CD19 single-target CART in R\/R DLBCL: a single-center retrospective study. Front Immunol. 2025;16:1582944.","journal-title":"Front Immunol"},{"key":"1755_CR56","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029532","author":"MB Geyer","year":"2025","unstructured":"Geyer MB, DeWolf S, Mi X, Weis K, Shaffer BC, Cadzin B, et al. CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia. Blood. 2025. https:\/\/doi.org\/10.1182\/blood.2025029532.","journal-title":"Blood"},{"key":"1755_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00262","volume":"10","author":"R Epperly","year":"2020","unstructured":"Epperly R, Gottschalk S, Velasquez MP. A bump in the road: how the hostile AML microenvironment affects CAR T cell therapy. Front Oncol. 2020;10:262.","journal-title":"Front Oncol"},{"key":"1755_CR58","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1172\/JCI78753","volume":"125","author":"Y Sun","year":"2015","unstructured":"Sun Y, Oravecz-Wilson K, Mathewson N, Wang Y, McEachin R, Liu C, et al. Mature T cell responses are controlled by microRNA-142. J Clin Invest. 2015;125:2825\u201340.","journal-title":"J Clin Invest"},{"key":"1755_CR59","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.imlet.2023.08.005","volume":"262","author":"M Hasiuk","year":"2023","unstructured":"Hasiuk M, D\u00f6lz M, Marone R, Jeker LT. Leveraging micrornas for cellular therapy. Immunol Lett. 2023;262:27\u201335.","journal-title":"Immunol Lett"},{"key":"1755_CR60","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","volume":"23","author":"K Paunovska","year":"2022","unstructured":"Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23:265\u201380.","journal-title":"Nat Rev Genet"},{"key":"1755_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.610","volume":"11","author":"H Wang","year":"2021","unstructured":"Wang H, Sun J, Zhang B, Zhao D, Tong H, Wu H, et al. Targeting miR-126 disrupts maintenance of myelodysplastic syndrome stem and progenitor cells. Clin Transl Med. 2021;11:e610.","journal-title":"Clin Transl Med"},{"issue":"4","key":"1755_CR62","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nm.4499","volume":"24","author":"B Zhang","year":"2018","unstructured":"Zhang B, Nguyen LXT, Li L, Zhao D, Kumar B, Wu H, et al. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med. 2018;24(4):450\u201362.","journal-title":"Nat Med"},{"key":"1755_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26420-7","volume":"12","author":"L Zhang","year":"2021","unstructured":"Zhang L, Nguyen LXT, Chen Y-C, Wu D, Cook GJ, Hoang DH, et al. Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance. Nat Commun. 2021;12:6154.","journal-title":"Nat Commun"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01755-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01755-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01755-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T16:04:05Z","timestamp":1762963445000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01755-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1755"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01755-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human sample acquisition was approved by the City of Hope Institutional Review Board (protocol numbers 18067, 07047 and 06229) at the City of Hope National Medical Center, in accordance with an assurance filed with and approved by the Department of Health and Human Services and met all requirements of the Declaration of Helsinki. Mouse care and experiments were performed in accordance with federal guidelines and under the Institutional Animal Care and Use Committee (IACUC) at the City of Hope approved protocol (#15,005).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}